Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Cerbios-Pharma SA has 2 pending office actions in Biotechnology & Pharmaceuticals. Both matters are handled by 1 examiner in 1 art unit, and UNDERDAHL, THANE E is the busiest examiner with 2 pending actions.
The active docket is fully concentrated in one examination channel. A coordinated response strategy may therefore be practical, particularly if the applications present related technical or claim issues. Developments in one matter may also provide useful guidance for managing the other.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| UNDERDAHL, THANE E | 2 | 58.8% | +50.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18874238 | COMBINED USE OF A PROBIOTIC AND BUTYRIC ACID TO INCREASE THE ENTEROCYTE'S HEALTH AND CONSEQUENTLY THE WELLNESS OF PETS AND LIVESTOCK | UNDERDAHL, THANE E | — |
| 18865311 | PROBIOTIC FOR USE IN THE TREATMENT OF INFLAMMATORY ALTERATIONS OF THE INTESTINAL MUCOSA, PARTICULARLY OBESITY | UNDERDAHL, THANE E | — |
| Art Unit | Apps |
|---|---|
| 1699 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18874238 | COMBINED USE OF A PROBIOTIC AND BUTYRIC ACID TO INCREASE THE ENTEROCYTE'S HEALTH AND CONSEQUENTLY THE WELLNESS OF PETS AND LIVESTOCK | UNDERDAHL, THANE E | 1699 | §102§103DP | Non-Final OA | — | Pending | Dec 12, 2024 |
| 18865311 | PROBIOTIC FOR USE IN THE TREATMENT OF INFLAMMATORY ALTERATIONS OF THE INTESTINAL MUCOSA, PARTICULARLY OBESITY | UNDERDAHL, THANE E | 1699 | §102§103§112DP | Non-Final OA | — | Pending | Nov 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCerbios-Pharma SA has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Thane E Underdahl has the most, with 2 of Cerbios-Pharma SA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
